| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | lenalidomide | FIMM | pan-cancer | AAC | -0.088 | 0.6 |
| mRNA | ML334 diastereomer | CTRPv2 | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | KU-55933 | GDSC1000 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | -0.024 | 0.6 |
| mRNA | pifithrin-mu | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | 17-AAG | FIMM | pan-cancer | AAC | -0.091 | 0.6 |